SB 202190 hydrochloride is the salt form of SB 202190.SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 with selective, cell-permeable, and antitumor activity, and also induces differentiation of human embryonic stem cells to cardiomyocytes.

p38α:50 nM (IC50), p38β2:100 nM (IC50)

Methods: SB 202190 hydrochloride (0-10 μM, 0-72 hours) was used to treat a subset of colorectal cancer (CRC) cell lines (RKO, CACO2, and SW480), and cell growth was measured.
Results: SB 202190 hydrochloride inhibited the growth of a subset of colorectal cancer (CRC) cell lines in a dose- and time-dependent manner. [1]

Methods: SB 202190 hydrochloride (dissolved in 100% DMSO and then diluted with normal saline (NS) to a final DMSO concentration of 0.1%, injected intracerebroventricularly) was administered to rats, and both the VaD model group and the sham operation group received an equal volume of 0.1% DMSO injected ICV. Eight rats in each group were examined in the Morris water maze to assess spatial learning and memory, six rats were sacrificed and brain sections were prepared for TUNEL staining and Bcl-2/caspase-3 immunohistochemistry, and six rats were sacrificed and tissue homogenates were prepared for Western blot assay of phosphorylated p38 MAPK expression.
Results: Compared with the model group, the SB 202190 hydrochloride group showed a significantly shorter escape latency in the Morris water maze hidden platform test; compared with VaD model rats, the SB 202190 hydrochloride group also showed significantly reduced hippocampal neuronal apoptosis (P < 0.01) as well as higher (anti-apoptotic) Bcl-2 expression and lower (pro-apoptotic) caspase-3 expression. [2]